C1C=C(Cl)C=C(C(OO)=[O:9])C=1.[C:12]([O:16][C:17](=[O:43])[NH:18][CH:19]1[CH2:24][CH2:23][CH:22]([NH:25][C:26]2[N:31]=[C:30]3[NH:32][N:33]=[C:34]([C:35]4[CH:40]=[CH:39][N:38]=[C:37]([S:41][CH3:42])[N:36]=4)[C:29]3=[CH:28][N:27]=2)[CH2:21][CH2:20]1)([CH3:15])([CH3:14])[CH3:13]>ClCCl.CO>[C:12]([O:16][C:17](=[O:43])[NH:18][CH:19]1[CH2:24][CH2:23][CH:22]([NH:25][C:26]2[N:31]=[C:30]3[NH:32][N:33]=[C:34]([C:35]4[CH:40]=[CH:39][N:38]=[C:37]([S:41]([CH3:42])=[O:9])[N:36]=4)[C:29]3=[CH:28][N:27]=2)[CH2:21][CH2:20]1)([CH3:15])([CH3:14])[CH3:13]m-CPBA (490 mg, 2.41 mmol) was added slowly to a solution of {-4-[3-(2-methylsulfanyl-pyrimidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (from Example 18 supra) (550 mg, 1.21 mmol) in a mixture of dichloromethane and methanol (20 mL, 1:1). The reaction mixture was stirred at room temperature for 25 minutes. The solvent was then removed under reduced pressure and the solid was purified by column chromatography (silica gel, 20 g, 200-300 mesh, eluting with dichloromethane:methanol, 5:1) to afford {4-[3-(2-methanesulfinyl-pyrimidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester. (Yield 300 mg, 52.9%).